Q3 FY23 Earnings Presentation

ESG Appendix Q3 FY23 Revenue by portfolio and geography Worldwide U.S. Table of Executive Portfolio Financial Guidance & Contents Summary Highlights Highlights Assumptions Non-U.S. Developed Emerging Markets Revenue ($M)¹ As reported Y/Y% Organic Y/Y% Revenue ($M)¹ As reported Y/Y% Organic Y/Y% Revenue ($M)¹ As reported Y/Y% Organic Y/Y% Revenue ($M)¹ As reported Y/Y% Organic Y/Y% Cardiovascular 2,772 1.0% 6.5% 1,375 6.0% 6.0% 859 -8.1% 3.6% 538 4.9% 13.1% Cardiac Rhythm & 1,431 2.1% 7.5% Hearth Failure Structural Heart & 760 2.7% 8.8% Aortic Coronary & Peripheral Vascular 581 -3.6% 1.5% Medical Surgical 2,137 -6.7% -1.6% 965 -2.5% -2.5% 760 -6.4% 5.5% 412 -15.6% -11.7% Surgical Innovations 1,425 -6.2% -0.9% Respiratory, Gastrointestinal, & Renal 712 -7.7% -3.0% Neuroscience 2,248 4.9% 7.3% 1,507 7.9% 6.1% 401 -7.0% 5.1% 341 7.9% 15.8% Cranial & Spinal 1,128 2.4% 5.3% Technologies Specialty Therapies 699 10.4% 11.4% Neuromodulation 420 2.7% 6.1% Diabetes 570 -2.4% 3.3% 215 -15.7% -15.7% 274 5.0% 16.9% 80 17.6% 20.6% Total Medtronic 7,727 -0.5% 4.1% 4,062 3.1% 2.5% 2,294 -5.9% 6.0% 1,371 -1.0% 5.4% 1) Data has been intentionally rounded to the nearest million and, therefore, may not sum 25 Q3 FY23 Earnings Presentation | February 21, 2023 Medtronic

View entire presentation